---
title: The present and future for CAR-T cell therapy in adult B-cell ALL
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316713/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed
  the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL),
  with FDA approval of tisagenlecleucel (tisa-cel) for pediatric/young adult patients
  and brexucabtagene autoleucel (brexu-cel) for adults. Efficacy is contingent upon
  several factors including disease burden. Emerging data suggests that bridging therapy,
  lymphodepletion and for some patients, consolidation therapy have an ...
disable_comments: true
---
Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA approval of tisagenlecleucel (tisa-cel) for pediatric/young adult patients and brexucabtagene autoleucel (brexu-cel) for adults. Efficacy is contingent upon several factors including disease burden. Emerging data suggests that bridging therapy, lymphodepletion and for some patients, consolidation therapy have an ...